Patent ID: 7981917

Claim:
A pharmaceutical composition useful for triggering apoptosis in a cell associated with a cancer selected from glioblastoma multiforme, breast carcinoma, pancreatic carcinoma, Burkett's lymphoma, multiple myeloma, neuroblastoma, prostate cancer, colorectal cancer, recurring cancer, metastatic breast cancer, chemo-resistant tumors or drug-resistant cancer, said composition comprising a combination of: a pharmaceutically effective amount of a first compostion comprising a compound having a general formula: wherein, R 1 is methyl, fluoromethyl, difluoromethyl, trifluoromethyl, alkyl, fluoroalkyl, difluoroalkyl, trifluoroalkyl, polyfluoroalkyl, hydroxyalkyl, or carboxyalkyl; R 2 is hydrogen, fluoro, chloro, bromo; fluoromethyl, difluoromethyl, trifluoromethyl, alkyl, fluoroalkyl, difluoroalkyl, trifluoroalkyl, polyfluoroalkyl, hydroxyalkyl, or carboxyalkyl; R 3 -R 7 are independently selected from a group consisting of: hydrogen, fluoro, chloro, bromo, alloxy, alkyl, fluoroalkyl, difluoroalkyl, trifluoroalkyl, polyfluoroalkyl, hydroxyalkyl, or carboxyalkyl, aryl and heteroaryl; R 8 -R 11 are independently selected from a group consisting of: hydrogen, fluoro, chloro, bromo; fluoromethyl, difluoromethyl, trifluoromethyl, alkyl, fluoroalkyl, difluoroalkyl, trifluoroalkyl, polyfluoroalkyl, hydroxyalkyl, or carboxyalkyl; and R 12 is hydrogen, acetyl, acyl, alkyl, fluoroalkyl, difluoroalkyl, trifluoroalkyl, polyfluoroalkyl, hydroxyalkyl, carboxyalkyl; aminoacyl, aminoalkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; a pharmaceutically effective amount of a second composition capable of increasing the concentration of misfolded or damaged proteins in the ER, wherein said second composition comprises a compound selected from bortezomib nelfinavir, atazanavir, fosamprenavir, ritonavir, of indinavir, and a pharmaceutically acceptable carrier.